• Incyte will present oncology data at the European Society for Medical Oncology Congress in Madrid on Oct. 23-27, 2026.
• Presentations will feature INCB161734, a KRAS G12D inhibitor, and INCA33890, a bispecific antibody; both are in ongoing Phase 3 programs.
• An investor event and webcast on Oct. 26, 2026, from 2:30-4:00 p.m. ET will cover key data and portfolio updates.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Incyte Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 202610181805BIZWIRE_USPR_____20261018_BW477134) on October 18, 2026, and is solely responsible for the information contained therein.